Comparison of IMD management between baseline, first evaluation and second evaluation cohorts
| Baseline (2005–2006) | First evaluation (2011–2012) | Second evaluation (2013–2015) | |
| Total IMD cases | 24 | 22 | 29 |
| Serogroup | n=22 | ||
| B | 41% (10) | 86% (19) | 62% (18) |
| C | 29% (7) | 5% (1) | – |
| Y | – | 5% (1) | 28% (8) |
| W135 | 4% (1) | 5% (1) | 10% (3) |
| Unknown | 25% (4) | – | – |
| Case fatality ratio | 4% (1/24) | 9% (2/22) | 17% (5/29) |
| Triage score appropriate | N/A | 50% (11/22) | 64% (16/25) |
| ED re-presentation | 36% (8/22) | 18% (4/22) | 21% (6/29) |
| Median time to documented medical review (mins) | 15 (range 0–120) | N/A | 21 (range 0–265) |
| Proportion of cases with delayed clinical public health notification | N/A | 44% (7/16) | 48% (13/27) |
| Median time to intravenous antibiotics from triage | 79 (range 3–213) | N/A | 66 (range 0–820) |
| Median time to intravenous antibiotics from medical review (min) | 39.5 (n=16) | N/A | 25.0 (n=24) |
| Antibiotics within 1 hour of assessment | 66% (10/15) | 36% (8/22) | 66% (19/29) |
N/A=Data not available. Denominator varies by data completeness for each field.
IMD, invasive meningococcal disease.